CONC
COM:CONCORDBIOTECH
Concord Biotech
- Stock
Last Close
2,031.55
25/11 09:20
Market Cap
176.73B
Beta: -
Volume Today
7.43K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | ||
|---|---|---|---|---|---|---|
average inventory | 1.32B - | 1.74B 31.67% | 2.04B 16.83% | 2.10B 3.15% | ||
average payables | 588.15M - | 647.51M 10.09% | 884.53M 36.60% | 941.18M 6.40% | ||
average receivables | 2.05B - | 2.36B 15.26% | 2.86B 21.04% | 3.12B 8.90% | ||
book value per share | 73.62 - | 95.53 29.75% | 105.45 10.39% | 123.31 16.93% | 145.93 18.34% | |
capex per share | -14.86 - | -19.52 31.33% | -14.86 23.84% | -13.87 6.70% | 8.19 159.06% | |
capex to depreciation | -7.32 - | -7.42 1.37% | -3.11 58.12% | -2.69 13.58% | 1.60 159.55% | |
capex to operating cash flow | -1.00 - | -1.22 21.90% | -0.75 38.76% | -0.59 21.31% | 0.32 154.73% | |
capex to revenue | -0.31 - | -0.34 8.31% | -0.22 35.06% | -0.17 20.43% | 0.09 149.15% | |
cash per share | 19.19 - | 19.23 0.22% | 15.46 19.60% | 16.42 6.16% | 27.29 66.25% | |
days of inventory on hand | 295.36 - | 465.96 57.76% | 400.27 14.10% | 393.24 1.76% | 310.08 21.15% | |
days payables outstanding | 189.15 - | 140.74 25.59% | 170.49 21.14% | 173.73 1.90% | 140.81 18.95% | |
days sales outstanding | 144.28 - | 128.96 10.62% | 133.71 3.69% | 137.50 2.84% | 127.86 7.02% | |
debt to assets | 0.06 - | 0.08 36.42% | 0.05 36.95% | 0.02 56.23% | 0.00 82.42% | |
debt to equity | 0.07 - | 0.09 32.19% | 0.06 36.59% | 0.02 56.83% | 0.00 83.31% | |
dividend yield | 0.01 - | 0.00 92.92% | 0.01 1,135.91% | 0.01 24.05% | 0.00 15.29% | |
earnings yield | 0.02 - | 0.02 38.89% | 0.02 25.53% | 0.02 37.25% | 0.02 18.51% | |
enterprise value | 99.03B - | 99.37B 0.35% | 99.15B 0.22% | 98.81B 0.34% | 155.12B 56.98% | |
enterprise value over ebitda | 44.34 - | 29.72 32.98% | 33.72 13.49% | 26.26 22.14% | 33.29 26.79% | |
ev to operating cash flow | 63.95 - | 59.57 6.85% | 47.79 19.78% | 40.17 15.95% | 58.43 45.47% | |
ev to sales | 19.88 - | 16.45 17.24% | 14.00 14.93% | 11.90 15.00% | 15.54 30.65% | |
free cash flow per share | -0.06 - | -3.57 5,896.63% | 4.97 239.11% | 9.65 94.18% | 17.18 78.15% | |
free cash flow yield | -0.00 - | -0.00 5,896.63% | 0.01 239.11% | 0.01 94.18% | 0.01 13.12% | |
graham net net | 22.35 - | 24.37 9.03% | 23.36 4.12% | 27.59 18.09% | 45.66 65.50% | |
graham number | 163.64 - | 219.68 34.24% | 199.18 9.33% | 252.33 26.68% | 310.96 23.24% | |
income quality | 0.72 - | 0.53 26.40% | 0.87 63.75% | 0.76 12.54% | 0.86 12.78% | |
intangibles to total assets | 0.00 - | 0.01 5,388.64% | 0.00 49.77% | 0.00 95.15% | 0.00 42.30% | |
interest coverage | 262.07 - | 440.04 67.91% | 40.89 90.71% | 61.82 51.17% | 200.32 224.04% | |
interest debt per share | 5.04 - | 8.60 70.51% | 6.50 24.43% | 3.45 46.96% | 0.89 74.05% | |
inventory turnover | 1.24 - | 0.78 36.61% | 0.91 16.41% | 0.93 1.79% | 1.18 26.82% | |
invested capital | 0.07 - | 0.09 32.19% | 0.06 36.59% | 0.02 56.83% | 15.41B 63,008,491,199,503.77% | |
market cap | 98.53B - | 98.53B 0% | 98.53B 0% | 98.53B 0% | 155.17B 57.48% | |
net current asset value | 3.68B - | 4.24B 15.12% | 4.23B 0.21% | 5.04B 19.06% | 7.22B 43.37% | |
net debt to ebitda | 0.22 - | 0.25 13.19% | 0.21 16.42% | 0.07 64.56% | -0.01 115.56% | |
net income per share | 16.16 - | 22.45 38.89% | 16.72 25.53% | 22.95 37.25% | 29.45 28.33% | |
operating cash flow per share | 14.80 - | 15.95 7.73% | 19.83 24.37% | 23.51 18.57% | 25.38 7.91% | |
payables turnover | 1.93 - | 2.59 34.40% | 2.14 17.45% | 2.10 1.87% | 2.59 23.38% | |
receivables turnover | 2.53 - | 2.83 11.88% | 2.73 3.56% | 2.65 2.76% | 2.85 7.55% | |
research and ddevelopement to revenue | 0.03 - | 0.03 0.85% | 0.04 14.24% | 0.03 8.40% | 0.02 31.33% | |
return on tangible assets | 0.18 - | 0.20 11.06% | 0.13 33.10% | 0.16 18.70% | 0.18 14.25% | |
revenue per share | 47.62 - | 57.74 21.25% | 67.72 17.28% | 79.40 17.25% | 95.40 20.16% | |
roe | 0.22 - | 0.24 7.05% | 0.16 32.54% | 0.19 17.37% | 0.20 8.44% | |
roic | 0.18 - | 0.20 14.91% | 0.14 29.86% | 0.16 11.19% | 0.31 93.96% | |
sales general and administrative to revenue | 0.01 - | 0.01 7.15% | 0.01 27.18% | 0.01 15.35% | 0.01 11.81% | |
shareholders equity per share | 73.62 - | 95.53 29.75% | 105.45 10.39% | 123.31 16.93% | 145.93 18.34% | |
stock based compensation to revenue | ||||||
tangible asset value | 7.70B - | 9.93B 28.93% | 11.00B 10.74% | 12.90B 17.29% | 15.26B 18.34% | |
tangible book value per share | 73.62 - | 94.91 28.93% | 105.11 10.74% | 123.29 17.29% | 145.90 18.34% | |
working capital | 4.23B - | 5.01B 18.40% | 4.77B 4.77% | 5.36B 12.22% | 7.54B 40.72% |
All numbers in INR (except ratios and percentages)